Pancreatic cancer is one of the most aggressive forms of cancer, killing about 95% of patients within 5 years of diagnosis. Traditional therapies, despite extensive efforts, have not been shown to significantly improve survival rates. Our project aims to develop an immunotheraphy-based treatment using multi-component drug carriers to treat pancreatic cancer.